Lucas recently joined the Alacrita team as a consultant in the Cambridge office, following the sale of CerSci Therapeutics, a biotech company that he founded in 2015. As CEO, Lucas lead CerSci through acquisition of its initial development program, mechanistic validation, preclinical studies, IND preparation and submission, Phase I studies, and ultimately through its acquisition by Acadia Pharmaceuticals (NASDAQ: ACAD), while supporting fundraising, business development and investor relations throughout. As a consultant, Lucas brings practical operational expertise in a start-up biotech company, combined with his scientific background and experience thereof. He has broad therapeutic area experience including oncology, CNS (neurodegenerative disease), pain, metabolic disorders, bone, liver disease, and cardiovascular disease.
Lucas’ academic background includes a BS from Baylor University in biology with a minor in chemistry, with an MS and a PhD in biomedical engineering from The University of Texas at Dallas.